ImageneBio (IMA) to Release Earnings on Thursday

Key Points

• Ikena Oncology is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.14) per share.
• The company's stock has seen a 4.5% decline and currently trades at $15.75, with a market cap of $63.32 million.
• Insider transactions reveal significant stock purchases, with Director Otello Stampacchia acquiring 267,556 shares at an average price of $29.90 per share.

ImageneBio (NASDAQ:IMA - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect ImageneBio to post earnings of ($0.14) per share for the quarter.

ImageneBio (NASDAQ:IMA - Get Free Report) last issued its earnings results on Thursday, July 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08. On average, analysts expect ImageneBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ImageneBio Stock Down 0.2%

Shares of IMA traded down $0.03 during mid-day trading on Friday, reaching $14.67. 5,894 shares of the company's stock were exchanged, compared to its average volume of 48,362. The company has a 50-day simple moving average of $16.15 and a two-hundred day simple moving average of $15.70. ImageneBio has a 52-week low of $11.65 and a 52-week high of $23.28. The company has a market cap of $58.97 million, a price-to-earnings ratio of -1.91 and a beta of 0.51.

Wall Street Analysts Forecast Growth

Separately, Wedbush dropped their price objective on shares of ImageneBio from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Friday, July 25th.

Insider Buying and Selling

In other news, Director Otello Stampacchia bought 267,556 shares of the stock in a transaction on Friday, July 25th. The stock was purchased at an average cost of $29.90 per share, with a total value of $7,999,924.40. Following the purchase, the director owned 454,982 shares of the company's stock, valued at approximately $13,603,961.80. The trade was a 142.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director David P. Bonita bought 83,611 shares of the stock in a transaction on Friday, July 25th. The stock was purchased at an average cost of $29.90 per share, with a total value of $2,499,968.90. Following the completion of the purchase, the director directly owned 287,885 shares in the company, valued at $8,607,761.50. This trade represents a 40.93% increase in their position. The disclosure for this purchase can be found here. Company insiders own 5.94% of the company's stock.

Institutional Trading of ImageneBio

An institutional investor recently raised its position in ImageneBio stock. Goldman Sachs Group Inc. boosted its position in ImageneBio, Inc. (NASDAQ:IMA - Free Report) by 62.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 76,464 shares of the company's stock after acquiring an additional 29,369 shares during the period. Goldman Sachs Group Inc. owned about 0.16% of ImageneBio worth $98,000 at the end of the most recent reporting period. Institutional investors own 75.00% of the company's stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.